Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 62332-103

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 62332-103). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aripiprazole 1figure)

This is a table that shows the effect of different drugs on aripiprazole, a medication used for treating symptoms of schizophrenia and bipolar disorder. The drugs included in the table are categorized according to their interaction with specific enzymes involved in the metabolism of aripiprazole. The table displays changes in the amount of aripiprazole (reported as fold change) relative to a reference value (without interacting drug). Additionally, the table reports the maximum concentration of some of the interacting drugs in the blood (Cmax). The drugs listed include ketoconazole, sunitinib, carbamazepine, and famotidine, among others.*

FDA Label Image

Figure 2 (Aripiprazole 2figure)

FDA Label Image

Figure 4 (Aripiprazole 4figure)

This seems to be data from a study concerning special populations and their response to a certain medication. The data include variables such as age, gender, hepatic impairment, renal impairment and metabolizer status. There is also a graph showing the fold change in the medication's effects. However, without more context or information, it is difficult to provide a more specific description or analysis of the data.*

FDA Label Image

Figure 5 (Aripiprazole 5figure)

FDA Label Image

Aripiprazole-6figure.jpg (Aripiprazole 6figure)

This is a chart displaying the proportion of subjects with relapse for Aripiprazole and Placebo. It also provides the number of subjects at risk for each group over a 182-day period.*

FDA Label Image

Aripiprazole-7figure.jpg (Aripiprazole 7figure)

This appears to be a graph with two lines, one labeled "Aripiprazole" and the other labeled "Placebo". The x-axis is labeled "Days from Randomization" and the y-axis is labeled "Proportion with Relapse". The data points for the Aripiprazole line are 83, 74, 62, 56, 53, 52, 48, 45, 41 (corresponding to the x-axis values of 14, 28, 42, 56, 70, 84, 98, 112, 126) and the data points for the Placebo line are 75, 61, 58, 50, 47, 46, 43, 42 (corresponding to the x-axis values of 14, 28, 42, 56, 70, 84, 98, 112). The rest of the text seems to be describing the graph so is not relevant for generating the description.*

FDA Label Image

Figure 3 (Aripiprazole Figure3)

FDA Label Image

Aripiprazole mg 15

FDA Label Image

Aripiprazole mg10

FDA Label Image

Structure (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.